Eurosurv. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

[tetano]

• Anne J Huiberts[SUP]1[/SUP] , Brechje de Gier[SUP]1[/SUP] , Christina E Hoeve[SUP]1[/SUP] , Hester E de Melker[SUP]1[/SUP] , Susan JM Hahné[SUP]1[/SUP] , Gerco den Hartog[SUP]1,2[/SUP] , Janneke HHM van de Wijgert[SUP]1,3[/SUP] , Susan van den Hof[SUP]1[/SUP] , Mirjam J Knol[SUP]1[/SUP]

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV-2 infection was 31% in 18–59-year-olds and 14% in 60–85-year-olds. Protection of Omicron infection was higher than of bivalent vaccination without prior infection. Although bivalent booster vaccination increases protection against COVID-19 hospitalisations, we found limited added benefit in preventing SARS-CoV-2 infection.


https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.7.2300087#html_fulltext